All four Danish centers have started screening Multiple Myeloma patients for OV’s APO010 Study
Hoersholm, Denmark, October 07th, 2016 – Oncology Venture Sweden AB (OV:ST) today announced that all four planned centers have been opened for inclusion of Multiple Myeloma patients in the screening study for phase 2 with Oncology Ventures Immuno Oncology drug APO010 as planned. Approximately 150 patients will be screened using OV’s DRP™ (Drug Response Predictor). The screening study aims to identify 15 Multiple Myeloma patients with the highest likelihood to benefit from treatment with APO010. The 15 patients are to be included in a focused phase 2 multi-center study. If the product already